CRDF Gains 33.18%

CRDF (CRDF:NASDAQ) shot up at $11.6, representing a gain of 33.2%. On Fri 18 Sep 20, CRDF:NASDAQ touched a New 2-Week High of $8.71. The stock appeared on our News Catalysts scanner on Thu 17 Sep 20 at 08:17 AM in the 'BIOTECH' category. From Fri 04 Sep 20, the stock recorded 44.44% Up Days and 40.00% Green Days

The stock spiked on Thu 17 Sep 20 at $11.18 with a volume of 47M+.

About CRDF (CRDF:NASDAQ)

Cardiff Oncology Inc is a clinical-stage oncology therapeutics company, developing onvansertib, a first-in-class, 3rd generation, oral and highly-selectivePolo-like Kinase 1 (PLK1) inhibitor to treat patients with leukemia, lymphoma and solid tumor cancers. The company is making advancements in its clinical development program, with three ongoingclinical trials: a Phase 1b/2 trial in Acute Myeloid Leukemia (AML); aPhase 2 trial in metastatic Castration-Resistant Prostate Cancer (mCRPC)and a Phase 1b/2 trial in metastatic Colorectal Cancer (mCRC). The firm's treatment includes KRAS-mutated metastatic colorectal cancer (mCRC), metastatic castrate-resistant prostate cancer (mCRPC) and acute myeloid leukemia (AML).